Cyclerion Therapeutics (CYCN) Equity Average (2019 - 2025)
Historic Equity Average for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to $9.1 million.
- Cyclerion Therapeutics' Equity Average rose 663.68% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.1 million, marking a year-over-year increase of 663.68%. This contributed to the annual value of $10.1 million for FY2024, which is 736.89% down from last year.
- Latest data reveals that Cyclerion Therapeutics reported Equity Average of $9.1 million as of Q3 2025, which was up 663.68% from $8.7 million recorded in Q2 2025.
- Cyclerion Therapeutics' 5-year Equity Average high stood at $60.8 million for Q3 2021, and its period low was $4.5 million during Q2 2023.
- In the last 5 years, Cyclerion Therapeutics' Equity Average had a median value of $10.6 million in 2024 and averaged $22.6 million.
- Its Equity Average has fluctuated over the past 5 years, first plummeted by 8545.56% in 2023, then soared by 10612.67% in 2024.
- Over the past 5 years, Cyclerion Therapeutics' Equity Average (Quarter) stood at $52.3 million in 2021, then plummeted by 74.22% to $13.5 million in 2022, then decreased by 10.44% to $12.1 million in 2023, then decreased by 29.44% to $8.5 million in 2024, then rose by 6.22% to $9.1 million in 2025.
- Its last three reported values are $9.1 million in Q3 2025, $8.7 million for Q2 2025, and $8.8 million during Q1 2025.